| Project/Area Number |
15K10346
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
ASAI Akio 関西医科大学, 医学部, 教授 (50231858)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岩田 亮一 関西医科大学, 医学部, 助教 (60580446)
伊藤 量基 関西医科大学, 医学部, 准教授 (70434826)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | グリオーマ / 膠芽腫 / 癌幹細胞 / 樹状細胞 / 免疫抑制 / 免疫治療 / テモゾロミド / がん幹細胞 |
|---|
| Outline of Final Research Achievements |
Glioblastoma multiforme (GBM) is the most fatal malignant primary brain tumor. GBM contains functional subsets of cells called glioblastoma stem-like cells (GSCs), which are radioresistant and chemoresistant and eventually lead to tumor recurrence. We established GSCs lines and analyzed the expression of immune-associated molecules. GSCs lines were positive for MHC-Ⅰ, which indicated that GSCs can be recognized by T cells. Temozolomide (TMZ) is an oral alkylating agent with established anti-tumor activity in patients with GBM. We focused on the TMZ function and explored its influence on human dendritic cells (DCs) subsets. TMZ suppressed the secretion of IL-10 from DCs. Moreover, the addition of TMZ into peripheral blood mononuclear cells with DCs significantly enhanced the DC mediated ex vivo expansion and expression of cytotoxic molecules in CD8+ T cells. Our present findings suggest that TMZ is a potential anti-tumor reagent suitable for the combination use with DC-vaccine therapy.
|
